期刊文献+

异基因外周血干细胞移植治疗白血病并发症分析及防治 被引量:3

Analysis of the prevention of the complications of 40 leukemia patients treated by allogeneic peripheral blood hematopoietic stem cell transplantation
下载PDF
导出
摘要 目的探讨不含全身照射(TBI)预处理方案异基因外周血干细胞移植(allo-PBSCT)治疗40例白血病并发症的发生情况及其防治。方法分析我院2001年1月~2008年10月allo-PBSCT治疗的40例患者临床资料。40例的供者均为HLA-Ⅰ/Ⅱ抗原完全相合的同胞,采用不含TBI改良Bu/Cy及减低剂量Bu+Arac+CTX+氟达拉滨(Flu)预处理方案。氨磷汀预防口腔黏膜炎,前列腺素E1预防肝静脉闭塞病(HVOD);40例均在预处理及移植后造血恢复期应用更昔洛韦预防巨细胞病毒(CMV)感染,采用环胞菌素A和短程MTX进行GVHD的预防。结果40例患者中出现Ⅰ度口腔黏膜炎23例(57.6%),Ⅱ度口腔黏膜炎4例(10%)。Ⅳ度口腔黏膜炎2例(0.5%);40例患者中均未发生急性GVHD及急性CMV感染;19例(47.5%)出现慢性GVHD,出血性膀胱炎(HC)发生率0.5%,间质性肺炎(IP)发生率0.25%;40例均未出现肝静脉闭塞病(HVOD);40例移植患者中5例(12.5%)死于慢性GVHD移植相关并发症。结论预处理及移植后造血恢复期应用更昔洛韦预防CMV感染治疗,可能会减少移植患者CMV感染;使用细胞保护剂氨磷汀可能会减少或减轻移植患者口腔黏膜炎发生;慢性GVHD已日益成为影响异基因外周血干细胞移植后期生命及生活质量的重要因素。 Objective To analyze the prevention of the complications of 40 leukemia patients treated by allogeneic peripheral blood stem cell transplantation (alIo-PBSCT) of non-intradiation pretreatment.Methods To analyze clinical datas of 40 leukemia patients underwent allo-PBSCT from HLA-identical siblings in our hospital from January 2001 to October 2008.The conditioning regimen consisted of the high dose combination chemotherapy:Busulfan (Bu) + Cytarabine (Ara-c) + cyclophosphamide (CTX) + Me-CCNU and a decreased dose combination chemotherapy:Bu+Ara-c + CTX+ Fludarabine(Flu).Amifostine,Prostaglandin EI,Ganciclovir ,Cyclosporine-A (CsA) plus Methotrexate (MTX) ware respectively given to prevent oral mucosal ulcers,HVOD,CMV infection, GVHD.Results In 40 patients,23 cases had Ⅰ degree of oral mucositis(57.6%),4 cases with Ⅱ degree of oral mucositis(10%), 4 cases with Ⅳ degree of oral mucositis(0.5%).The incidence of Hemorrhagic cystitis and Interstitial pneumonia were separately 0.5%,0.25%.All of survivals did't have acute GVHD,CMV infection and HVOD. 19 cases(47.5%) had chronic GVHD,whose complications were the main causes of death to 5 cases of them.Conclusion Using Ganciclovir for during pretreatment period and hematopoietic recovery period may reduce the probability of CMV infection;Using Amifostine may reduce the probability of oral mucosal ulcers;Chronic GVHD has been an important factor to affect the quality of life of patients treated by allo-PBSCT in later period.
出处 《江西医药》 CAS 2009年第3期189-192,共4页 Jiangxi Medical Journal
关键词 异基因 造血干细胞移植 预处理 并发症 Allogeneic stem cell transplantaion pretreatment complications
  • 相关文献

参考文献6

  • 1周洁,郭乃榄,郑缓,卢锡京,黄晓军,史琪,吴彤,范蕴明,张耀臣,陈欢,邓星明,许兰平,江滨,陆道培.异基因骨髓移植两种预处理方案的比较[J].中华血液学杂志,1996,17(2):64-66. 被引量:24
  • 2Cutler C ,Antin JH.Peripheral blood stem cell for allogeneic Transplantation :a review .Stem Cell ,2001,19:108.
  • 3MAZUR L,BLAWATA. Effects of GSH and WR-2721 on induction of micronuclei by cyclophosphamide .Toxicol Lett , 1999,110( 102):67.
  • 4MAZUR L,CZYZEWSKA A.lnhibition of the clastogenic effect of cyclophosphamide by WR-2721 in the Bone Marrow of Mice.Mutat Res,1994,309(2) :219.
  • 5东星月,李晓冰,杜红光,汪运山.新型细胞保护剂——氨磷汀[J].肿瘤防治杂志,2004,11(8):888-890. 被引量:11
  • 6GeorgiaB.Vogelsang ,How I treat chronic graft-versus-host disease. Blood,2001,97 : 1196.

二级参考文献20

  • 1Glover D,Glick J H,Weiler C,et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide:a controlled phase Ⅱ trial[J]. J Clin Oncol, 1986,4(4):584-588.
  • 2Kemp G, Rose P, Vurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities results of a randomized control trial in patiets with advanced ovarian cancer [J]. J Clin Oncol, 1996, 14(7):2101-2112.
  • 3Illiano A, Barlettae,De Marino V, et al. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase Ⅱ study[J]. Anticancer Res, 2000,20(5C):3999-4003.
  • 4Genviesse I , Lange C, Schanz J, et al. Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy a comparative study[J].Anticancer Drugs,2001,12(4):345-349.
  • 5Bohuslavizki K H, Klutmann S, Bleckmann C,et al . Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer [J]. Strahlenther Onkol,1999,75(2):57-59.
  • 6Bourhis J,De Crevoisier R, Abdulkarin B,et al Arandomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2000,45(5):1105-1108.
  • 7Buntael J,Kuttner K,Frohlich D,et al . Sclective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer[J] . Ann Oncol, 1998, 9(5):471-473.
  • 8Coia L R,Brown D Q, Hardiman J. WR-2721 as cytotoxic and radioprotective agent in treatment of murine lymphoma with total dody irradiation[J]. Natl Cancer Inst Monogr,1998, 15(6):235-239.
  • 9Liu T,Liu Y, He S, et al. Use of radiation with or without WR-2721 in advanced reetal cancer[J]. Cancer,1992,69(11):2820-2825.
  • 10工令玮.放射线及化学治癌药物保护剂[J].临床医学(台湾),2001,47(2):92-95.

共引文献32

同被引文献46

  • 1杨孝顺,李雪梅,安梅,王惠萱,邓淑芬.机采血小板与冷沉淀联合输注在大出血治疗中的应用[J].中华检验医学杂志,2004,27(7):464-464. 被引量:23
  • 2杨孝顺,安梅,王惠萱,李雪梅,邓淑芬.冰冻单采血小板与冷沉淀联合应用治疗创伤性失血[J].中国输血杂志,2004,17(6):440-441. 被引量:29
  • 3颜霞,徐晓东,侯悦,徐捷,韩红霞,王丽娟,胡伟,董霜,孙慧,钱慧军.4例异基因造血干细胞移植患者急性移植物抗宿主病重度皮肤损伤的护理[J].中华护理杂志,2006,41(1):38-40. 被引量:21
  • 4姚慧青,胡永红,高小华,罗淑兰,黄建云,杨惠宽.异基因造血干细胞移植的血小板输注27例分析[J].临床和实验医学杂志,2007,6(9):97-97. 被引量:3
  • 5Desai PH,Dinesh Kurian MD,Nannan Thirumavalavan BS,et al.A Randomized Clinical Trial Investigating the Relationship Between Aprotinin and Hypercoagulability in Off-Pump Corona ry Surgery.Anesth Analg.2009;109(5):1387-1394.
  • 6Rahe-Meyer N,Pichlmaier M,Haverich A,et al.Bleeding Management with fibrinogen concentrate targeting a high-normal Plasma fibrinogen level:a pilot study.British J Anaesthesia.2009;102(6):785-792.
  • 7中华人民共和国国务院.医疗机构管理条例,1994:26
  • 8赵洪美.26例外周血造血干细胞移植患者的口腔护理[J]中华现代护理学杂志,2008(23):2154-2155.
  • 9Paul P,Rouas-FreissN,Moreau P,et al. HLA-G,-E,-F prework- shoptools and protocols for analysis of non-clasical class I genes transcription protein expression [J]. Hum Immunol, 2000,61 (11) : 1177-1195.
  • 10Lee N,Goodlett DR,Ishitani A,et al. HLA-E surface expression depends on binding of TAP-dependent peptides derived from cer- tain HLA class I signal sequences [J]. J Immunol, 1998,160(10): 4951-4960.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部